CD3-CD56+ natural killer cells

CD3-CD56+ natural killer cells (Masonic Cancer Center, University of Minnesota) is an investigational allogeneic cellular immunotherapy being developed for the treatment of acute myeloid leukemia (AML). The product consists of highly purified natural killer (NK) cells derived from a haploidentical donor. The manufacturing process utilizes the Miltenyi Biotec CliniMACS Cell Selection System to perform a two-step enrichment: first depleting CD3+ T cells (to minimize the risk of graft-versus-host disease) and then positively selecting for CD56+ NK cells. This results in a product with high NK cell purity (typically >70%). These cells are intended to provide a graft-versus-leukemia (GvL) effect by recognizing and eliminating leukemic blasts. In clinical protocols, the cells are often activated with cytokines such as recombinant human IL-15 prior to infusion and are administered following a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, with post-infusion IL-2 support to facilitate cell survival and expansion.

Other names

CD3-depleted CD56-selected natural killer cellsCD-3-depleted CD56-selected natural killer cellsCD 3-depleted CD56-selected natural killer cellshaploidentical natural killer cellsallogeneic NK cellsCD3-negative CD56-positive lymphocytesCD-3-negative CD56-positive lymphocytesCD 3-negative CD56-positive lymphocytes